Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar fishmouse (< 20) Submitted: 9/10/2009 7:05:18 PM : Outperform Start Price: $1.74 DVAX Score: +95.57

dvax

Featured Broker Partners


Advertisement